Singapore & Berlin | 1 April 2025 – Restalyst Pte Ltd, a Singapore-based biotech innovator, has entered a strategic collaboration with Charité – Universitätsmedizin Berlin, a world-leading academic medical center, to advance the early detection of hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. This partnership will focus on evaluating the diagnostic potential of ERBB3, a key cancer-linked biomarker, alongside Restalyst’s proprietary HCC-REAAD™ algorithm, to enhance early and accurate HCC diagnosis.

With HCC often diagnosed at late stages when treatment options become limited, this collaboration seeks to improve patient outcome through enhancing early detection methods to address this critical unmet need in global oncology. By combining Charité’s extensive clinical expertise in hepatology with Restalyst’s cutting-edge diagnostic technology, the study aims to develop a more reliable and accessible screening approach for high-risk populations.

Zaccheus Peh, CEO of Restalyst Pte Ltd, stated: “Partnering with Charité, a pioneer in medical research, marks a pivotal step in validating ERBB3’s role in HCC and optimising our HCC-REAAD™ algorithm. Together, we can transform early cancer detection and save lives.”

The study’s outcome could reshape HCC screening protocols, and equip clinicians with a powerful tool to identify at-risk patients earlier and improve long-term outcomes.

About Restalyst Pte Ltd
Restalyst Pte Ltd is a Singapore-based biotechnology company at the forefront of precision diagnostics, dedicated to developing innovative diagnostic solutions for early disease detection. Its flagship HCC-REAAD™ algorithm leverages advanced analytics to enhance HCC diagnosis, enabling timely and targeted interventions.

About Charité – Universitätsmedizin Berlin
Charité – Universitätsmedizin Berlin, a cutting-edge medical institution, is a leader in diagnosis and treatment of particularly severe, complex, and rare diseases and health conditions. A medical school and university medical center in one, Charité has earned an outstanding reputation worldwide, combining first-class patient care with excellence in research and innovation, state-of-the-art teaching, and high-quality training and education. At Charité, people and their health come first. Charité is dedicated to transformative translational research, applying the very latest scientific findings to prevention, diagnostics, and treatment and harnessing clinical observations to develop new lines of research and scientific questions. Charité’s foremost goal is to actively help shape the medicine of the future. https://www.charite.de/en/

For media inquiries, contact:
Ivan Lim
Restalyst Pte Ltd
info@restalyst.com